Most cited papers from Apexigen (United States)

Apexigen (United States)

What are the most cited papers from Apexigen (United States)?

The most cited paper from Apexigen (United States) is "Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial" (Lacey Padrón et al., 2022), with 381 citations. Next come "CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study" (311) and "NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023" (213).

Published TypeFieldAccessCitations

Showing 18 of 18 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial Lacey Padrón et al. · Nature Medicine Open access	Jun 2022	381
2	CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study Mark H. O’Hara et al. · The Lancet Oncology	30 Dec 2020	311
3	NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023 Al B. Benson et al. · Journal of the National Comprehensive Cancer Network Open access	Jul 2023	213
4	A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1 Sarah Ann Weiss et al. · Clinical Cancer Research Open access	17 Jun 2021	102
5	Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children’s Oncology Group (ACNS1221) Lucie Lafay‐Cousin, Éric Bouffet, Douglas R. Strother et al. · Journal of Clinical Oncology Open access	27 Nov 2019	78
6	A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy Sarah Ann Weiss, Mario Sznol, Montaser F. Shaheen et al. · Clinical Cancer Research Open access	3 Aug 2023	73
7	LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade Amber Hickman et al. · Journal of Clinical Investigation Open access	12 May 2022	44
8	APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application Erin L. Filbert, Pia Björck, Minu K. Srivastava et al. · Cancer Immunology Immunotherapy Open access	3 Jan 2021	38
9	Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma Yongwoo David Seo et al. · JAMA Oncology Open access	12 Oct 2023	31
10	A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better Dijana Djureinovic et al. · Molecular Cancer Open access	14 Nov 2023	15
11	1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers A.H. Ko, M. Noel, J. Chao et al. · Annals of Oncology Open access	Sep 2022	11
12	Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer Maira Soto, Erin L. Filbert, Hai Liang Yang et al. · Cancer Research Communications Open access	5 Jan 2024	10
13	A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers Andrew H. Ko, Joseph Chao, Marcus Smith Noel et al. · Cancer Research Communications Open access	Feb 2025	8
14	Updates in Clinical Management of Pancreatic Cancer Andrew H. Ko · Journal of the National Comprehensive Cancer Network Open access	May 2024	4
15	Nanobody-Based Detection of Ywhag Protein as a Cerebrospinal Fluid (Csf) Diagnostic Biomarker for Alzheimer's Disease: an in Silico Study Rehman Arif, Gaurav Sharma Conference paper	10 Oct 2025	0
16	Aptamer-Mediated Inhibition of von Willebrand Factor (vWF) to Prevent Platelet Overactivation in Myocardial Ischemia-Reperfusion Injury: An in Silico Study Alina Sohail, Gaurav Sharma Conference paper	10 Oct 2025	0
17	Computational Modeling of scFv Constructs and Aptamer-Based Strategies for CAR T-Cell Optimization and Enrichment Aarya Kapil Gupta, Gaurav Sharma Conference paper	3 Jul 2025	0
18	Computational Simulations and Structural Analysis of Bispecific Aptamers Targeting Dual Biomarkers for Enhanced Ovarian Cancer Diagnosis Vyom Sharma, Gaurav Sharma Conference paper	19 Nov 2025	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.